M&A Deal Summary |
|
|---|---|
| Date | 2011-07-18 |
| Target | Victory Pharma |
| Sector | Life Science |
| Buyer(s) | Shionogi |
| Sellers(s) |
Ampersand Capital Partners
EW Healthcare Partners |
| Deal Type | Add-on Acquisition |
| Deal Value | 127M USD |
SEARCH BY
Try For Free 7-Day Free Trial
Shionogi Inc. is the U.S.-based group company of Shionogi & Co., Ltd., a leading Japanese pharmaceutical company. Shionogi Inc., develops and commercializes pharmaceutical products that address unmet medical needs. Together with our Japanese corporate parent, Shionogi has been providing innovative medicines essential to people's health for over 130 years. This partnership sets the stage for further expansion of our global business with expectations for Shionogi Inc. to become an even more significant contributor to our world-wide results.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 2 |
| Sector (Life Science) | 1 of 2 |
| Type (Add-on Acquisition) | 1 of 2 |
| State (California) | 1 of 2 |
| Country (United States) | 1 of 2 |
| Year (2011) | 1 of 1 |
| Size (of disclosed) | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2016-04-06 |
Shionogi - Keflex
United States Shionogi - Keflex (cephalexin capsules, USP) is a first-generation cephalosporin antibiotic shown to be active against strains of both gram-positive and gram-negative aerobes in vitro and in clinical infections. |
Sell | - |
| Category | Growth Capital Firm |
|---|---|
| Founded | 1988 |
| PE ASSETS | 2.0B USD |
| Size | Large |
| Type | Sector Focused |
Ampersand Capital Partners is a middle-market private equity group that concentrates on growth equity investment opportunities in the healthcare sector. The Firm looks to invest $10 to $100 million in businesses with $10 to $100 million of revenue. Specific areas of interests within healthcare include lab products, specialty diagnostic equipment, pharmaceutical outsourcing, and specialty pharma. Ampersand generally prefers to be the first and sole institutional investor. Ampersand was formed in 1988 and is based in Wellesley, Massachusetts.
| DEAL STATS | # |
|---|---|
| Overall | 16 of 53 |
| Sector (Life Science) | 6 of 24 |
| Type (Add-on Acquisition) | 11 of 38 |
| State (California) | 3 of 8 |
| Country (United States) | 16 of 50 |
| Year (2011) | 1 of 2 |
| Size (of disclosed) | 9 of 13 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2011-07-14 |
CoreLab Partners
Princeton, New Jersey, United States CoreLab Partners, Inc. is a provider of linical trials, medical image assessment, and cardiac safety solutions. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2011-08-29 |
Modified Polymer Components
Sunnyvale, California, United States Modified Polymer Components, Inc. is specializes in the design, development, and manufacture of highly precise polymer components and assemblies. MPC’s extensive production capabilities enable it to perform secondary operations for all types of polymer tubing, including complex multilumen extrusions, to create ramps, tips, and almost any imaginable feature. |
Buy | - |
| Category | Growth Capital Firm |
|---|---|
| Founded | 1985 |
| PE ASSETS | 3.0B USD |
| Size | Large |
| Type | Sector Focused |
Essex Woodlands Health Ventures is a growth equity and venture capital specialist investment firm focused on opportunities across the healthcare sector. Specific areas of interest include biotechnology, pharmaceuticals, medical devices, and healthcare services/IT. Historically, Essex invested primarily in early and later-stage situations; however, today the firm also makes growth capital investments between $20 - $60 million in companies valued between $50 - $250 million, as well as private investments in public entities (PIPEs). Essex Woodlands was formed in 1985 and offices in Palo Alto, California; New York City; Houston, Texas; Shanghai and London.
| DEAL STATS | # |
|---|---|
| Overall | 26 of 53 |
| Sector (Life Science) | 10 of 17 |
| Type (Add-on Acquisition) | 17 of 34 |
| State (California) | 10 of 17 |
| Country (United States) | 22 of 46 |
| Year (2011) | 4 of 5 |
| Size (of disclosed) | 18 of 22 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2011-05-16 |
Orthovita
Malvern, Pennsylvania, United States Orthovita is a unique spine/orthopedic surgical biomaterials company offering advanced bone regeneration and soft tissue healing technologies. Their experience lies in developing and distributing novel, high-tech, synthetic-based biomaterial products. Orthovita currently has four key commercial product platforms: Vitoss Bone Graft Substitute, Vitagel Surgical Hemostat, Cortoss Synthetic Cortical Bone, and Imbibe Delivery and Disposable Systems. |
Sell | $316M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2011-09-06 |
BreatheAmerica
Nashville, Tennessee, United States BreatheAmerica develops and operates diagnostic and treatment centers for chronic airway and immune system-related diseases. Through its allergy, sinus and asthma programs and immune therapy programs, BreatheAmerica centers concentrate the resources needed to diagnose and care for these interrelated and complex diseases that affect 25% of the country’s population. BreatheAmerica is based in Nashville, Tennessee. |
Buy | - |
